SNIBE(300832) 搜狐财经·2025-04-25 12:47Core Viewpoint - The company announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 1.3 yuan per share, totaling approximately 1.021 billion yuan, which represents 55.86% of its net profit, marking the sixth cash distribution since its listing [1][2]. Financial Performance - The company reported a revenue of 4.535 billion yuan for the fiscal year, reflecting a year-on-year growth of 15.41% [2]. - The net profit reached 1.828 billion yuan, with a year-on-year increase of 10.57% [2]. - Basic earnings per share were reported at 2.3271 yuan, and the weighted average return on equity was 22.85% [2]. Dividend History - The company has a history of cash distributions since its listing, with the following details: - 2024: 10 shares for 13 yuan (total 1.021 billion yuan, dividend yield 1.85%) [2] - 2023: 10 shares for 10 yuan (total 786 million yuan, dividend yield 1.63%) [2] - 2022: 10 shares for 7 yuan (total 550 million yuan, dividend yield 1.51%) [2] - 2021: 10 shares for 6 yuan (total 472 million yuan, dividend yield 0.89%) [2] - 2020: 10 shares for 10 yuan (total 412 million yuan, dividend yield 0.62%) [2] - 2020 (interim): 10 shares for 15 yuan (total 619 million yuan, dividend yield 0.97%) [2] Market Activity - The stock experienced a net outflow of 12.258 million yuan from major funds today, with a total outflow of 34.114 million yuan over the past five days [2]. - The latest margin financing balance for the stock was reported at 854 million yuan, with a decrease of 8.9404 million yuan over the past five days, representing a decline of 1.04% [3]. Industry Comparison - Within the pharmaceutical and biotechnology sector, 248 companies have announced their 2024 dividend plans, with WuXi AppTec leading with a total cash distribution of 7.692 billion yuan [3]. - Other notable companies include Yunnan Baiyao and Aier Eye Hospital, with cash distributions of 2.114 billion yuan and 1.4887 billion yuan, respectively [3].